- Policy
- Eun-kyung Jeong “will review limited INN prescriptions”
- by Lee, Jeong-Hwan Jul 28, 2025 06:08am
- Minister of Health and Welfare Eun-Kyung Jeong plans to review a plan to allow limited adoption of international nonproprietary name prescriptions for essential medicines with unstable supply. However, she drew a line on the full introduction of INN prescriptions in place of brand-name prescriptions as a measure to address issues such as
- Policy
- Measures to ban imports of psychotic dietary supplements
- by Lee, Hye-Kyung Jul 28, 2025 06:07am
- The Ministry of Food and Drug Safety (MFDS; Minister, Yu-Kyoung Oh) announced on July 25 that the Ministry is designating '7-Hydroxymitragynine,' an ingredient that is narcotic (antipsychotic), as a prohibited material and ingredient for import into South Korea. This measure was implemented to ban overseas direct purchase of dietary suppleme
- Policy
- Jeong Eun-kyeong "Pharma·biotech·healthcare powerhouse"
- by Lee, Jeong-Hwan Jul 25, 2025 06:10am
- Jeong Eun-kyeong, inaugurated as the Minister of Health and Welfare, has declared her commitment to driving healthcare reform that wins over the public and the medical community, along with implementing a scientific estimation of the appropriate medical personnel, such as doctors, through the activation of the Estimation Committee for Requir
- Policy
- Daewoong, Kolon enter Ofev generic market at the same price
- by Lee, Tak-Sun Jul 25, 2025 06:09am
- Daewoong Pharmaceutical and Kolon Pharma will additionally enter the generic market for “Ofev Soft Cap (Nintedanib Esylate),” a treatment for chronic fibrotic interstitial lung disease. Competition is expected to intensify in the market with two more generic versions entering the market following Yungjin and Ildong Pharmaceutical’s ent
- Policy
- Reimb criteria established for Roche's DLBCL drug 'Polivy'
- by Lee, Tak-Sun Jul 25, 2025 06:08am
- The reimbursement criteria for Roche Korea's Polivy (polatuzumab vedotin), a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), have been successfully established by the Health Insurance Review & Assessment Service's (HIRA) Cancer Disease Review Committee (CDRC). This drug, which is garnering attention as the first DL
- Policy
- Eun-Kyung Jeong appointed as new MOHW Minister
- by Lee, Jeong-Hwan Jul 24, 2025 11:38pm
- With the appointment of Eun-kyung&160; Jeong (60, Seoul National University College of Medicine) as Minister of Health and Welfare, efforts to institutionalize and legislate telemedicine, as well as to establish a prescription drug delivery system, are expected to gain momentum. The government will begin establishing specific measures to
- Policy
- Jeong Eun-kyung views "orphan disease fund establishment"
- by Lee, Jeong-Hwan Jul 24, 2025 11:38pm
- Jung Eun-kyung, the candidate for Minister of Health and Welfare (MOHW), has expressed skepticism regarding the establishment of a separate fund to improve the National Health Insurance reimbursement rate for treatments for expensive, rare (orphan), and severe diseases. The rationale is that if the required financial scale for reimbursing
- Policy
- Release of Boryung’s generic version of Stivarga imminent
- by Lee, Tak-Sun Jul 24, 2025 06:07am
- The price of the liver cancer drug Stivarga Tab 40mg (regorafenib, Bayer) will be adjusted following the termination of the risk-sharing agreement due to the anticipated listing of its generic versions. Among the many companies, Boryung is expected to be the first company to launch a generic version of Stivarga in Korea. According to
- Policy
- Ruling party introduces another bill to reimburse abortion
- by Lee, Jeong-Hwan Jul 24, 2025 06:07am
- Following Representative In-soon Nam of the Democratic Party of Korea, Representative Sujin Lee of the same party submitted a bill on the 23rd to legally allow artificial termination of pregnancy through drugs such as Mifegyne and to apply health insurance reimbursement to surgical and pharmaceutical abortion procedures. The partial amend
- Policy
- Supply shortage of Parkinson’s drug Equfina is expected
- by Lee, Hye-Kyung Jul 23, 2025 06:08am
- Eisai Korea's Parkinson's disease treatment ‘Equfina Film-Coated Tab 50mg (safinamide mesilate)’ is expected to be in short supply for the next month, causing inconvenience to patients. In particular, although there are drugs with similar efficacy to Equfina, there are no direct therapeutic substitutes available with the same ingredie
